Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for SILO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 4.886M
March 31, 2026 5.682M
December 31, 2025 6.305M
September 30, 2025 5.009M
June 30, 2025 4.917M
March 31, 2025 4.011M
December 31, 2024 5.034M
September 30, 2024 6.782M
June 30, 2024 5.958M
March 31, 2024 5.292M
December 31, 2023 6.177M
September 30, 2023 7.497M
June 30, 2023 8.296M
March 31, 2023 9.444M
December 31, 2022 10.34M
September 30, 2022 11.85M
June 30, 2022 7.874M
March 31, 2022 8.503M
December 31, 2021 9.062M
September 30, 2021 10.15M
June 30, 2021 3.766M
March 31, 2021 4.228M
December 31, 2020 1.281M
September 30, 2020 2.070M
June 30, 2020 2.704M
Date Value
March 31, 2020 0.1382M
December 31, 2019 0.3771M
September 30, 2019 0.2987M
June 30, 2019 0.5029M
March 31, 2019 0.6927M
December 31, 2018
September 30, 2018 1.406M
June 30, 2018 1.305M
March 31, 2018 1.621M
December 31, 2017 1.603M
September 30, 2017 1.396M
June 30, 2017 1.915M
March 31, 2017 1.991M
December 31, 2016 1.246M
September 30, 2016 1.390M
June 30, 2016 1.821M
March 31, 2016 2.255M
December 31, 2015 2.360M
September 30, 2015 2.415M
June 30, 2015 2.864M
March 31, 2015 2.835M
December 31, 2014 2.769M
September 30, 2014 2.816M
June 30, 2014 2.491M
March 31, 2014 2.921M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics